Milei Threatens Falkland Oil Firms With Sanctions 
Anthropic IPO Marketing Expected to Start in Mid-October 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
 - EconoTimes)
Add as a preferred source on Google
NEW YORK, Feb. 15, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Tesaro, Inc. ("Tesaro") (NASDAQ:TSRO) securities between March 14, 2016 and January 12, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/tesaro-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) substantial undisclosed health risks, including anaphylaxis and anaphylactic shock, were associated with Tesaro's intravenous formulation of VARUBI (rolapitant); and (ii) as a result of the foregoing, Tesaro's shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages. On January 12, 2018, Tesaro announced it had updated the U.S. labeling of VARUBI (rolapitant) injectable emulsion packages after reports that some patients receiving the treatment experienced “Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions.”
If you suffered a loss in Tesaro you have until March 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/tesaro-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
